Table 3:
Dependent: 90 Day Mortality |
Survival, % (95% CI) |
HR (univariable), (95% CI, p value) |
HR (multivariable), (95% CI, p value*) |
HR (multivariable), (95% CI, p value**) |
|
---|---|---|---|---|---|
ASCA | <34 IU/ml | 80.0 (72.4-88.2) | - | ||
≥34 IU/ml | 59.1 (45.5-76.8) | 2.22 (1.15-4.30, p=0.017) | 3.27 (1.21-8.86, p=0.020) | 3.13 (1.11-8.82, p=0.031) | |
MELD | 1.11 (1.07-1.16, p<0.001) | 1.13 (1.07-1.19, p<0.001) | 1.13 (1.07-1.19, p<0.001) | ||
Dependent: 180 Day Mortality |
|||||
ASCA | <34 IU/ml | 63.4 (48.4-83.1) | |||
≥34 IU/ml | 29.9 (13.9-64.6) | 2.32 (1.28-4.21, p=0.006) | 3.48 (1.50-8.10, p=0.004) | 3.07 (1.30-7.28, p=0.011) | |
MELD | 1.10 (1.06-1.15, p<0.001) | 1.13 (1.08-1.18, p<0.001) | 1.12 (1.07-1.17, p<0.001) |
p value adjusted for MELD score, infection, antibiotics, steroids, pentoxifylline.
p value adjusted for MELD score, infection, antibiotics, steroids, pentoxifylline and LPS-BP. Likelihood ratio test. Bold font indicates significance (p value <0.05). HR, hazard ratio; CI, confidence interval; ASCA, anti-Saccharomyces cerevisiae antibodies; LPS-BP, lipopolysaccharide binding protein; MELD, Model for End-stage Liver Disease.